10-Q: Estrella Immunopharma Faces Nasdaq Delisting Amid Rising Losses

Estrella Immunopharma reported increased net losses and a growing accumulated deficit, receiving two Nasdaq non-compliance notices for minimum bid price and market value of listed securities.

Summary

• Reported a net loss of $5.5 million for the three months ended June 30, 2025, compared to $4.0 million for the same period in 2024.
• Incurred a net loss of $7.6 million for the six months ended June 30, 2025, up from $4.4 million for the same period in 2024.
• Accumulated deficit increased to $31.6 million as of June 30, 2025.
• Cash and cash equivalents stood at $1.3 million as of June 30, 2025, with a working capital deficit of $7.6 million.
• Research and development expenses rose to $4.7 million for Q2 2025 and $6.1 million for H1 2025, driven by clinical trial activities.
• General and administrative expenses increased to $0.9 million for Q2 2025 and $1.6 million for H1 2025, primarily due to professional fees and stock-based compensation.
• Received a Nasdaq notice on April 30, 2025, for non-compliance with the minimum $1.00 bid price rule, with a deadline of October 27, 2025, to regain compliance.
• Received a second Nasdaq notice on August 1, 2025, for non-compliance with the minimum $35 million Market Value of Listed Securities (MVLS) rule, with a deadline of January 28, 2026.
• Progressed the STARLIGHT-1 clinical trial with 6 patients dosed and a second clinical site activated as of June 30, 2025.
• Completed a private placement, receiving $1.35 million in gross proceeds as of June 30, 2025, out of an aggregate total of $3.35 million.
• Identified a material weakness in internal control over financial reporting due to a lack of qualified full-time personnel for complex U.S. GAAP accounting issues.

Sentiment

Score: 3

Explanation: The company reported increased net losses, a growing accumulated deficit, and a significant working capital deficit. Critically, it received two non-compliance notices from Nasdaq regarding its listing requirements, indicating severe market valuation issues and a high risk of delisting. While there was some capital raised and clinical trial progress, the overall financial health and market standing have deteriorated significantly.

Positives

• Progress in the Phase I/II STARLIGHT-1 clinical trial with 6 patients dosed and a second clinical site activated.
• Successfully raised $1.35 million in gross proceeds from a private placement offering as of June 30, 2025.
• Net cash used in operating activities significantly decreased to $0.9 million for the six months ended June 30, 2025, from $4.5 million in the prior year period.
• The Equity Line with White Lion, providing access to up to $50 million in capital, was extended to December 30, 2025.

Negatives

• Net loss increased to $5.5 million for Q2 2025 from $4.0 million for Q2 2024, and to $7.6 million for H1 2025 from $4.4 million for H1 2024.
• Accumulated deficit grew to $31.6 million as of June 30, 2025, from $23.9 million as of December 31, 2024.
• Total stockholders' equity shifted to a deficit of $6.1 million as of June 30, 2025, from a positive equity of $143,731 as of December 31, 2024.
• Received two non-compliance notices from Nasdaq for failing to maintain the minimum $1.00 bid price and $35 million Market Value of Listed Securities, posing a delisting risk.
• The common stock closing price of $0.84 as of August 6, 2025, is significantly below the $11.50 warrant exercise price, making warrant exercises an unlikely source of liquidity.
• Identified a material weakness in internal control over financial reporting due to insufficient qualified personnel for complex U.S. GAAP accounting.

Risks

• Inability to fund operations due to insufficient cash on hand or inability to raise additional debt or equity financing.
• Continued losses and negative cash flows until regulatory approval and sufficient revenue generation from product candidates.
• Dependence on the success of research and development programs, including EB103 and EB104.
• Risk of delisting from Nasdaq due to non-compliance with minimum bid price and Market Value of Listed Securities rules, which could adversely affect market liquidity, share price, and ability to raise capital.
• Reliance on Eureka for key research and development activities, manufacturing, and supply of clinical quantities, with potential adverse effects if the relationship terminates or services cannot be replaced on comparable terms.
• Limitations on issuing Equity Line Shares under the Common Stock Purchase Agreement without obtaining majority stockholder approval if such issuance would equal 20% or more of outstanding common stock.
• Potential for third parties to assert intellectual property infringement claims against the company, its licensors, or strategic collaborators.
• Impact of macroeconomic factors such as inflation rates, military action in Ukraine, and Israel's war against Hamas on financial position and operations.

Future Outlook

The company expects expenses to increase significantly as it continues to advance preclinical and clinical development of product candidates, seeks regulatory approval, scales clinical and regulatory capabilities, adapts compliance efforts for marketed products, maintains intellectual property, and incurs additional public company operational costs. It does not anticipate generating revenue for at least the next few years, with revenue generation contingent on regulatory approval and successful commercialization. Management believes it has sufficient funds for at least the next 12 months through existing cash and the ability to raise funds via the Equity Line Shares to White Lion, subject to certain limitations and stockholder approval.

Management Comments

• Management believes that the company has sufficient funds on hand and the ability to raise funds in the future through the issuance and sale of Equity Line Shares to White Lion to meet its working capital requirements and debt obligations for at least the next 12 months.
• We expect our research and development expenses to continue to increase as we advance IND filings, preclinical and clinical development, seek regulatory approval, scale capabilities, adapt compliance, protect intellectual property, and incur public company expenses.

Industry Context

The company operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on T-cell therapies for blood cancers and solid tumors. Its reliance on the ARTEMIS platform licensed from Eureka and collaboration with Imugene reflects common biotech strategies for leveraging specialized technology and sharing development costs. The significant losses and ongoing need for financing are typical for clinical-stage biopharma companies that have not yet commercialized a product, while the Nasdaq listing compliance issues indicate performance below typical public company standards for market capitalization and share price stability.

Comparison to Industry Standards

• The company's accumulated deficit and ongoing net losses are typical for a clinical-stage biopharmaceutical company that has not yet brought a product to market, as significant investment is required for research and development and clinical trials.
• The receipt of Nasdaq non-compliance notices for minimum bid price and Market Value of Listed Securities indicates that the company's market performance is currently below the standards expected for continued listing on a major exchange, which is a significant concern compared to established industry peers.

Corporate Governance

Legal Proceedings

• The company is from time to time party to certain legal proceedings and claims, but amounts accrued and reasonably possible losses are not deemed material to the unaudited condensed consolidated financial statements.
• There is a risk that third parties may assert infringement claims against the company, its licensors, or strategic collaborators based on existing or future patents.

Related Party Transactions

• Eureka Therapeutics, Inc. (Eureka): Estrella holds an exclusive license to Eureka's ARTEMIS platform for T-cell therapies, with milestone payments and single-digit royalties. Eureka is solely responsible for manufacturing and supply of clinical quantities. Estrella paid $3.5 million for initial milestones and deposited $1.5 million for patient treatment expenses under the STARLIGHT-1 SOW, with total fees of $33.0 million for all milestones. Accrued $8.8 million in related party liabilities for dosing milestones and site activation. Estrella also subleases office space from Eureka for $2,000 per month. Eureka collectively owned 68.2% of the company on a fully diluted basis as of June 30, 2025.
• CoFame Investment Holding LLC: Entered into a consulting agreement on November 1, 2024, for advisory services in Asia. Hong Zhang, CoFame's manager, is a director of the company. Accrued $18,333 in unpaid consulting fees as of June 30, 2025.
• White Lion: The company has a Common Stock Purchase Agreement (Equity Line) allowing it to require White Lion to purchase up to $50 million in common stock. 70,000 Equity Line Shares have been issued for $79,491 as of June 30, 2025. The agreement was extended to December 30, 2025.

Stakeholder Impact

• Shareholders: Face significant financial risks due to increasing net losses, a growing accumulated deficit, and a substantial working capital deficit. The Nasdaq non-compliance notices pose a material risk of delisting, which could severely impact share price and liquidity. Potential for dilution from future capital raises.
• Employees: Continued losses and liquidity concerns could impact job security and future compensation. Stock-based compensation is a component of remuneration, but its value is tied to stock performance.
• Creditors/Suppliers: Increased accrued liabilities to related parties (Eureka) indicate significant ongoing costs. The company's liquidity challenges could affect its ability to meet obligations to other creditors.
• Regulatory Bodies: The company must address Nasdaq's listing compliance requirements to avoid delisting. Progress in clinical trials (FDA IND clearance) is positive for product development.

Next Steps

• Continue to advance preclinical and clinical development of product candidates (EB103, EB104) and preclinical programs.
• Seek regulatory approval for any product candidates that successfully complete clinical trials.
• Scale up clinical and regulatory capabilities and adapt regulatory compliance efforts for marketed products.
• Maintain, expand, and protect the intellectual property portfolio.
• Add operational, financial, and management information systems and personnel to support product development and future commercialization.
• Monitor the bid price and Market Value of Listed Securities to regain Nasdaq compliance by October 27, 2025 (bid price) and January 28, 2026 (MVLS).
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) tax legislation on consolidated financial statements.
• Negotiate and enter into a clinical supply agreement and related quality agreement with Eureka.

Key Dates

Recommendation

The company is facing severe financial challenges, including increasing net losses, a substantial accumulated deficit, and a significant working capital deficit. The receipt of two non-compliance notices from Nasdaq for minimum bid price and market value of listed securities indicates a high risk of delisting, which would severely impair the stock's liquidity and valuation. While there is ongoing clinical trial progress and some capital has been raised, the fundamental financial deterioration and immediate delisting threat outweigh these positive developments, making the stock a high-risk investment with significant downside potential. The current stock price is also well below the warrant exercise price, making future capital from warrant exercises unlikely.

Keywords

Immunopharma, T-cell therapy, Cancer treatment, CD19, CD22, ARTEMIS, EB103, EB104, STARLIGHT-1, Clinical trial, Biopharmaceutical, Oncology, Nasdaq listing, Capital raise, SEC filing, 10-Q, Financial results, Research and development, Corporate governance, Risk factors